Loading stock data…
Zura Bio Limited (ZURA)
$5.23-0.06 (-1.13%)
Market ClosedLast close Jul 24
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Zura Bio Limited in the Healthcare sector is trading at $5.23 with a market capitalization of $366M. Wall Street consensus targets $15.67 (6 analysts), implying a +199.6% move over the next 12 months. The stock is currently 30% below its 52-week high of $7.44, remaining 5.7% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +199.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$25.50M↓ | -$18.41M↑ | -$19.52M↓ | -$18.06M↑ | -$19.25M |
| Net Income | -$24.22M↓ | -$17.18M↑ | -$18.04M↓ | -$15.99M↑ | -$17.44M |
Peer Comparison
JNJUNHPFE
Fundamentals
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody enginee...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$366.24M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-34.78%
Volume
Today's trading volume
366,205
Recent News
William Blair Starts Zura Bio (ZURA) at Outperform
Zura Bio Limited (NASDAQ:ZURA) is one of the 10 High Growth Stocks Insiders Are Buying. On July 8, 2026, William Blair initiated coverage of Zura Bio Limited (NASDAQ:ZURA) with an Outperform rating. The firm sees potential for the dual mechanism of action of tibulizumab to drive “differentiated efficacy” in two ongoing Phase 2 studies in […]
Here's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
One Zura Bio Insider Raised Their Stake In The Previous Year
Viewing insider transactions for Zura Bio Limited's ( NASDAQ:ZURA ) over the last year, we see that insiders were net...
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million
This biotech specializes in monoclonal antibody therapies for inflammatory and immunological diseases with significant unmet needs.
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges
RAPT Therapeutics develops oral therapies for oncology and inflammatory diseases, with lead candidates progressing in clinical trials.